The authors investigated the impact of heptavalent pneumococcal conjugate vaccine (PCV7) shortage on the rate of invasive pneumococcal disease (IPD). Vaccination status and number of doses delivered was determined. Regression analysis using an exponential decay model was used to predict the expected rate of IPD in the shortage period if IPD continued to decline at the same rate as in the availability period. The rate of IPD decreased from 15.5 to 6.5 with vaccine availability (P < .00001) and increased to 7.2 with shortage (P = .69). Based on the model, IPD rate would have been 3.6 if the decrease continued at the same rate when there was no shortage; this was statistically significant (95% prediction interval, 2.7-4.1). The rate of IPD correlated directly with the number of PCV7 doses delivered, r = -.98. Continuous availability of the PCV7 would have resulted in a statistically significant lower IPD rate compared to the measured IPD rate in the vaccine shortage period.
Centers for Disease Control and Prevention. Prevention of pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2000;49-49 (No. RR-9).
2.
Whitney CG, Farley MM, Hadler J, et al.Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348: 1737-1746.
3.
Kaplan SL, Mason EO, Wald ER, et al.Decrease in invasive pneumococcal infections in children among 8 children’s hospital in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113: 443-449.
4.
Lin PL, Michaels MG, Janosky J, Ortenzo M, Wald ER, Mason EO Jr.Incidence of invasive pneumococcal disease in children 3 to 36 months of age at a tertiary care pediatric center 2 years after the licensure of the pneumococcal conjugate vaccine. Pediatrics. 2003;111: 896-899.
5.
Centers for Disease Control and Prevention. Notice to readers: decreased availability of pneumococcal conjugate vaccine. MMWR. 2001;50: 783-784.
6.
Centers for Disease Control and Prevention. Notice to Readers: updated recommendations on the use of pneumococcal conjugate vaccine in a setting of vaccine shortage—Advisory Committee on Immunization Practices. MMWR. 2001;50: 1140-1142.
7.
Centers for Disease Control and Prevention. Notice to readers: pneumococcal conjugate vaccine shortage resolved. MMWR. 2003;52: 446-447.
8.
Centers for Disease Control and Prevention. Limited supply of pneumococcal conjugate vaccine: suspension of recommendation for fourth dose. MMWR. 2004;53: 108-109.
9.
Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR. 2004;53 (Dispatch): 1-2.
10.
Rennels MB, Edwards KM, Keyserling HL, et al.Safety and immunigenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998;101: 604-611.
11.
Black S, Shinefield H, Fireman B, Fireman B, Schwalbe J, Lewis E.Efficacy, safety and immunogenicity of heptava-lent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19: 186-195.
12.
Centers for Disease Control and Prevention. Updated recommendations for use of pneumococcal conjugate vaccine: reinstatement of the third dose. MMWR. 2004; 53: 589-590.
13.
Centers for Disease Control and Prevention. Notice to readers: pneumococcal conjugate vaccine shortage resolved. MMWR. 2004;53: 851-852.
Pigeon JG, Bohidar NR, Zhang Z, et al.Statistical models for predicting the duration of vaccine induces protection. Drug Information J. 1999;33: 811-819.
16.
Gellespie SH, Gosling RD, Charalambous BM.A reiterative model for calculating the early bactericidal activity of antituberculosis drugs. Am J Resp Crit Care Med. 2003;166: 31-35.
17.
Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF.Incidence of herpes zoster before and after varicella-vaccination-associated decrease in the incidence of varicella, 1992-2002. J Infect Dis. 2005; 191: 2002-2007.
18.
Pelton SI, Loughlin AM, Marchant CD.Seven valent pneumococcal conjugate vaccine immunization in two Boston communities: changes in serotypes and antimicrobial susceptibility among Streptococcus pneumoniae isolates. Pediatr Infect Dis J. 2004;23: 1015-1022.
19.
Byington CL, Samore MH, Stoddard GJ, et al.Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis. 2005; 41: 21-29.
20.
Centers for Disease Control and Prevention. Active Bacterial Core Surveillance. Available at: http://www.cdc.gov/ncidod/dbmd/abcs.
21.
Rathore MH, Dick M, Buckner P, Ayoub EM.Heamophilus influenzae type B invasive disease in urban and rural children: immunization patterns and prevalence of disease. South Med J. 1994;87: 1083-1087.
22.
Rutter M, Smith DJ, eds. Psychosocial Disorders in Young People: Time Trends and Their Causes. New York, NY: Wiley; 1995.
23.
Gangarosa EJ, Galazka AM, Wolfe CR, et al.Impact of anti-vaccine movements on pertussis control: the untold story. Lancet. 1998;351: 356-361.
24.
Savage E, Ramsay M, White J, et al.Mumps outbreak across England and Wales in 2004: observational study. BMJ. 2005;330: 1119-1120.
25.
Stoll ML, Rubin LG.Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine. Arch Pediatr Adolesc Med. 2004;159: 671-675.
